AR and prostate cancer: The pathogenesis of prostate cancer is mainly driven by androgen receptor (AR) activation and aberrant nuclear factor kappa B (NF-κB) signaling, and the interaction between both pathways enhances tumor aggressiveness and therapeutic resistance [2].